All In Biotech

Drug Trial Radar · NCT07172802

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as a Single Agent in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Apr 22, 2025

Primary completion

Feb 2027

Study completion Sep 2027

Sponsor

Lead sponsor
GI Innovation, Inc.Industry
Sponsor type
Industry
First posted
Sep 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Non-small Cell Lung Cancer (NSCLC)
  • Head and Neck (HNSCC)
  • Pancreatic Cancer
  • Renal Cell Carcinoma (RCC)

Interventions

  • GI-108Drug

    Dose level will be escalated from 0.1mg/kg to 1.5 mg/kg and Recommended phase 2 dose (or RP2D) of GI-108 will be administered via IV infusion Q3W upto 2 years (approximately 35 cycles)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs) (Dose escalation phase)Time frame: Study Day 1, assessed up to DLT period (3 weeks after treatment)
  2. Incidence and Severity of Immune-Related Adverse Events (irAEs) (Dose escalation phase)Time frame: From Day 1 through study completion (up to ~24 months)
  3. Objective Response Rate (ORR) according to RECIST version 1.1 (Dose expansion phase)Time frame: Study Day 1, assessed up to approximately 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Yonsei University Health System, Severance Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.